{
  "trial_id": "NCT02488993",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Diagnosis of cirrhosis",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patient is \u226518 years of age",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "Patient meets clinical eligibility to receive rifaximin-\u03b1 550 mg in the opinion of the participating physician, regardless of HE treatment actually received.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "West Haven Conn score of \u22652 at time of study entry (i.e. at provision of informed consent);",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "Mental health disorder such as dementia or psychosis which makes diagnoses of HE questionable;",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has a history of CLL and large cell transformation, with recent worsening lymphadenopathy. He has not had a significant response to previous treatments.",
  "_meta": {
    "topic_id": "8",
    "trial_id": "NCT02488993",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}